---
title: "Estrella Immunopharma regains Nasdaq compliance on bid price and market value"
url: "https://aibio.space/news/estrella-immunopharma-regains-nasdaq-compliance-bid-price-market-value/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-09-29"
section: "Listings"
tickers: "NASDAQ:ESLA"
source: "https://www.sec.gov/Archives/edgar/data/1844417/000121390025093197/ea0259355-8k_estrella.htm"
summary: "Nasdaq sent two letters on September 23, 2025 closing both matters. The company had been notified of the deficiencies in April and August."
---

By the aibio.space news desk.

Sources

- [Estrella Immunopharma, Inc. 8-K (2025-09-29)](https://www.sec.gov/Archives/edgar/data/1844417/000121390025093197/ea0259355-8k_estrella.htm)

[ESLA](https://aibio.space/companies/estrella-immunopharma/)

2025-09-29

# Estrella Immunopharma regains Nasdaq compliance on bid price and market value rules

Tickers [ESLA](https://aibio.space/companies/estrella-immunopharma/)

Nasdaq sent two letters on September 23, 2025 closing both matters. The company had been notified of the deficiencies in April and August.

## Key facts

- **Company**: Estrella Immunopharma, Inc. (NASDAQ: ESLA)

- **News type**: Listings

- **Primary source**: [Estrella Immunopharma, Inc. 8-K (2025-09-29)](https://www.sec.gov/Archives/edgar/data/1844417/000121390025093197/ea0259355-8k_estrella.htm)

*The White House and its lawn. CC0, via rawpixel. The picture shows the field, not the companies named.*

Estrella Immunopharma, Inc. said Nasdaq has confirmed it is back in line with two continued listing requirements.

On September 23, 2025, the Emeryville, California company received two letters from the Listing Qualifications Department of The Nasdaq Stock Market LLC, according to a [Form 8-K filing](https://www.sec.gov/Archives/edgar/data/1844417/000121390025093197/ea0259355-8k_estrella.htm).

The first letter covered the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2), which requires a closing bid of at least $1.00 per share. Nasdaq had told Estrella on April 30, 2025 that it was out of compliance. The letter states that for the 10 consecutive business days from September 9, 2025, through September 22, 2025, the stock's closing bid price was $1.00 per share or greater.

The second letter covered the minimum market value of listed securities requirement under Listing Rule 5550(b)(2). That test looks at the total market value of a company's listed shares. Nasdaq had notified the company on August 1, 2025 that it fell short. The letter states that for the 17 consecutive business days from August 28, 2025, through September 22, 2025, the company's market value of listed securities was $35,000,000 or greater.

For both matters, the filing says, "Nasdaq considers this matter closed."

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

ESLA

Estrella Immunopharma, Inc.

NASDAQ · United States

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/estrella-immunopharma-regains-nasdaq-compliance-bid-price-market-value/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Estrella Immunopharma regains Nasdaq compliance on bid price and market value", 2025-09-29, https://aibio.space/news/estrella-immunopharma-regains-nasdaq-compliance-bid-price-market-value/